clinic
experiment
prepar
iggsolubl
antigen
complex
well
form
follow
antibodi
therapi
vivo
multifacet
immun
regul
immun
complex
ic
test
human
anim
model
mostli
form
experiment
clinic
vaccin
least
centuri
intensifi
research
fcc
receptormedi
immun
modul
well
immun
complexdirect
antigen
process
present
inflammatori
respons
renew
interest
use
ic
vaccin
immunotherapi
current
icbas
immun
therapi
broadli
experi
hbv
hiv
viral
infect
control
antitumor
treatment
howev
mechanist
insight
icbas
treatment
rel
recent
subject
studi
strong
effort
need
establish
link
connect
laboratori
find
clinic
practic
review
cover
histori
mechan
vivo
outcom
safe
effect
therapeut
tool
clear
aim
bridg
laboratori
find
evolv
clinic
applic
wubbolt
r
et
al
fcrgammachain
itam
signal
critic
requir
crosspresent
solubl
antibodyantigen
complex
dendrit
cell
immun
complex
form
autoimmun
disord
tool
clinic
therapi
import
topic
modern
immunolog
bind
antigen
antibodi
immunolog
simpl
event
chang
properti
origin
ligand
result
modul
antigen
process
present
receptor
signal
inflammatori
respons
larger
scheme
antibodi
immun
therapi
becom
one
success
implement
biomed
technolog
modern
health
care
immunoglobulinbas
new
drug
rituximab
ipilimumab
alemtuzumab
among
highli
effect
cancer
treatment
sondak
et
al
scott
et
al
intraven
immunoglobulin
ivig
also
choic
treatment
autoimmun
pediatr
infect
antibodi
defici
schwab
nimmerjahn
contrast
use
classic
defin
ic
repres
old
subcategori
among
list
option
ic
vaccin
develop
clinic
intervent
becom
increasingli
sophist
larg
attribut
newli
gain
understand
fcc
receptor
fccr
ravetch
howev
icmedi
function
sole
control
via
receptor
engag
instanc
abil
transport
antigen
also
consider
anatom
locat
role
differ
stage
immun
induct
memori
format
modul
addit
spatiotempor
factor
year
ago
ic
vaccin
start
practic
use
antisera
complex
toxoid
corynebacteria
diphtheria
streptococcu
pyogen
decreas
side
effect
human
vaccin
copeman
et
al
olitzki
one
concern
approach
antigen
coat
antibodi
might
reduc
exposur
surfac
site
lead
limit
antibodi
product
concern
proven
unnecessari
subsequ
experi
olitzki
terr
et
al
report
mice
immun
human
bovin
serum
albumin
sensit
faster
specif
rabbit
antibodi
also
introduc
recipi
effect
seen
antigen
alon
combin
control
antiserum
terr
wolin
enhanc
optim
slight
antigen
excess
terr
wolin
terr
et
al
anoth
three
decad
use
peptid
hiv
rejuven
cell
hiv
carrier
berzofski
et
al
report
addit
antibodi
recogn
peptid
substanti
increas
prolif
index
cell
patient
berzofski
et
al
meantim
immun
complex
cast
neg
shadow
mainli
frequent
presenc
site
autoimmun
inflamm
lupu
membran
nephropathi
collect
call
type
iii
hypersensit
ic
deposit
rate
faster
clearanc
lead
robust
activ
complement
system
fc
receptor
signal
consequ
mononuclear
cell
degranul
antibodydepend
cellular
cytotox
adcc
releas
proinflammatori
cytokin
may
result
nydegg
effort
made
character
pathogen
ic
found
icmedi
attack
mainli
driven
inflammatori
cytokin
tnfa
warren
et
al
also
found
ic
form
low
affin
antibodi
tend
present
high
level
circul
deposit
readili
subendothelia
renal
capillari
loop
koyama
et
al
confirm
mice
genet
bred
produc
low
highaffin
antibodi
ic
chronic
form
former
deposit
glomeruli
devey
steward
earli
work
illumin
mechanist
insight
landmark
turn
point
ic
immun
regulatori
function
discoveri
fccr
attempt
understand
molecular
natur
antibodi
adsorb
splenocyt
report
boyden
sorkin
belkin
benacerraf
suggest
affin
mainli
afford
heavi
chain
antibodi
implic
structur
presenc
surfac
macrophag
interact
fc
portion
igg
berken
benacerraf
common
form
fccr
identifi
ravetch
kinet
subsequ
develop
current
paradigm
fc
receptor
biolog
nimmerjahn
ravetch
mous
activ
fccr
famili
consist
fccri
riii
riv
human
counterpart
includ
fccri
iia
iic
iiia
iiib
except
human
fccriiib
receptor
transmit
activ
signal
via
itam
motif
associ
common
cchain
intrins
present
cytoplasm
domain
speci
addit
inhibitori
receptor
fccriib
signal
via
cytoplasm
itim
domain
meticul
work
ravetch
et
al
gradual
delin
subtyp
specif
bind
strength
igg
subtyp
addit
presenc
lectinbas
type
ii
fccr
dcsign
sensit
glycosyl
state
fc
demonstr
recent
year
ravetch
bohm
et
al
relev
ic
fccr
signal
implic
least
three
aspect
activ
inhibit
receptor
affin
emerg
lectinbas
type
ii
fccr
ii
subclass
antibodi
bind
receptor
iii
highli
divers
express
receptor
host
cell
level
express
differ
stage
immun
activ
consider
becom
indispens
modern
applic
ic
nimmerjahn
ravetch
guilliam
et
al
backdrop
review
aim
provid
utilitarian
look
ic
perspect
clinic
applic
complement
current
pictur
antibodi
immun
therapi
crosspresent
cellular
immun
extracellular
antigen
default
antigen
present
pathway
take
solubl
cargo
via
endocytosi
process
progress
acid
endolysosom
vesicl
phdepend
chain
activ
cathepsin
amigorena
savina
load
onto
class
ii
molecul
solid
particl
engulf
via
phagocytosi
solubl
cargo
endocytos
via
receptormedi
uptak
rout
mhc
class
crosspresent
via
sever
mechan
lize
et
al
burgdorf
et
al
joffr
et
al
latter
activ
cell
known
crosspresent
becom
mechanist
basi
cellular
immun
antigen
origin
outsid
antigenpres
cell
apc
involv
ic
crosspresent
initi
note
assay
studi
vivo
tumor
kill
antibodi
tumor
inhibit
erad
antibodi
glossari
selftoler
break
immun
toler
refer
lack
immun
respons
antigen
result
central
thymic
select
peripher
lack
costimul
toler
educ
extrins
trigger
antigen
present
host
immun
complex
initi
specif
immun
recognit
toler
antigen
end
result
detriment
case
autoimmun
benefici
immun
attack
tumor
antigen
abil
antigen
contain
endophagocyt
vesicl
present
mhc
class
molecul
apc
surfac
contrast
convent
understand
class
antigen
origin
endogen
protein
synthesi
intens
studi
contest
topic
sever
lead
hypothes
includ
model
erphagosom
fusion
endocyticplasma
membran
recycl
cytosol
transloc
still
verifi
toxoid
richard
friedrich
johann
pfeiffer
classifi
bacteri
toxin
endotoxin
believ
sequest
cell
wall
exotoxin
thought
releas
surround
toxin
particularli
latter
thermal
chemic
deactiv
formalin
produc
toxoid
use
form
deactiv
vaccin
old
term
decreas
popular
modern
literatur
fc
fragment
crystalliz
region
simpli
refer
constant
region
antibodi
type
fccr
cell
surfac
receptor
express
mostli
cell
immun
system
bind
specif
fc
region
cimmunoglobulin
biolog
retent
refer
substanc
retain
biolog
system
use
context
antibodi
induct
antibodybas
treatment
term
usual
refer
deposit
ic
tissu
either
serv
sourc
persist
antigen
stimul
usual
desir
outcom
induc
uncontrol
immun
attack
often
seen
autoimmun
plasmablast
less
matur
plasma
cell
precursor
could
still
undergo
cell
divis
chemotaxi
gener
refer
movement
biolog
entiti
respons
chemic
stimulu
environ
immunolog
term
refer
immun
cell
movement
driven
surfac
express
chemotact
receptor
away
gradient
cognat
chemokin
erythroleukemia
form
acut
myeloid
leukemia
involv
cell
give
rise
erythrocyt
antigenemia
persist
antigen
circul
blood
antigenemia
use
indic
sever
infect
measur
efficaci
immun
intervent
express
cell
antibodi
kill
tumor
directli
effect
entir
depend
cell
fccr
cchain
vasov
et
al
logic
explan
today
bind
antibodi
facilit
tumor
antigen
process
dc
drove
antigenspecif
tcell
activ
vivid
confirm
ripmova
mice
wherebi
ova
transcript
control
rat
insulin
promot
infus
ovaspecif
cell
oti
effici
trigger
destruct
bcell
addit
ovaspecif
igg
antibodi
howev
led
sever
autoimmun
diabet
suggest
presenc
ic
overcom
toler
self
antigen
expect
breakdown
selftoler
requir
presenc
fccr
common
cchain
harber
et
al
crosspresent
extern
antigen
enhanc
antigen
associ
surfac
receptor
dc
shakushiro
et
al
burgdorf
et
al
chatterje
et
al
independ
studi
arriv
similar
conclus
presenc
ic
facilit
antigen
uptak
two
three
log
amigorena
bonnerot
schuurhui
et
al
howev
real
enhanc
antigen
present
measur
degre
tcell
activ
order
log
regnault
et
al
cchain
itam
domainmut
notam
mice
normal
surfac
express
fccr
extent
rescu
ic
uptak
howev
crosspresent
ova
ic
lost
boross
et
al
report
seem
indic
itam
requir
uptak
yet
behav
part
direct
intracellular
antigen
traffick
interestingli
dc
syk
defici
downstream
itam
phosphoryl
disrupt
crosspresent
ic
antigen
antigen
uptak
well
sedlik
et
al
differ
like
due
fact
syk
associ
broader
spectrum
inhibit
phagocyt
signal
mocsai
et
al
deep
mechanist
understand
ic
facilit
crosspresent
current
limit
one
report
icmedi
enhanc
crosspresent
requir
tap
protein
sensit
proteasom
inhibit
suggest
involv
cytosol
target
intern
antigen
regnault
et
al
system
icmedi
antigen
uptak
retain
complex
earli
endosom
rather
permit
matur
degrad
lysosom
chatterje
et
al
cohn
et
al
although
molecular
natur
shallow
target
unknown
find
agreement
contemporari
understand
reduc
cargo
digest
main
advantag
dc
antigen
present
apc
joffr
et
al
kotsia
et
al
hari
et
al
dc
subset
mous
peripheri
usual
consid
superior
crosspresent
development
overlap
popul
dc
known
similar
function
cell
phenotyp
mirror
human
dc
platzer
et
al
howev
cell
involv
icmedi
crosspresent
well
understood
joffr
et
al
strict
sens
standard
ic
ova
link
antibodi
specif
ctype
lectin
receptor
found
convent
dc
elicit
strong
tcell
activ
elimin
ovaposit
tumor
vivo
sancho
et
al
yet
deliv
host
ova
conjug
express
dc
respect
suppress
ovaexpress
tumor
similar
extent
neubert
et
al
antibodi
use
studi
carri
fc
mutat
disrupt
fccr
bind
prepar
might
function
mere
deliveri
vehicl
paper
therefor
address
effect
fccr
signal
crosspresent
anoth
report
bevan
group
suggest
fccrmediat
ic
crosspresent
essenti
dc
ic
uptak
process
dc
affect
absenc
fccr
den
haan
bevan
dc
rapidli
engulf
ic
sustain
stimul
capac
long
period
short
puls
bonifaz
et
al
influenza
viruschalleng
mice
absenc
extracellular
avail
ic
strongli
affect
primari
ctl
respons
flu
np
antigen
howev
recal
respons
limit
transfer
immun
serum
controlinfect
mice
restor
longterm
activ
np
antigen
leon
et
al
cross
lmt
bcelldefici
mice
cchain
knockout
mice
npspecif
respons
upon
viral
challeng
reduc
transfer
immun
serum
restor
primari
secondari
respons
lmt
mice
yet
fail
doubledefici
recipi
suggest
essenti
role
fccr
signal
crosspresent
observ
confirm
recent
studi
ic
associ
antigen
present
endocyt
vesicl
earli
endosom
lysosom
one
day
uptak
dissoci
antigen
take
place
along
rout
liu
et
al
fccrmediat
ic
signal
like
support
simultan
activ
cell
instanc
prostatespecif
antigencontain
ic
target
via
fccr
led
combin
activ
cell
mannos
receptor
target
associ
tcell
respons
alon
berlyn
et
al
regard
intracellular
antigen
traffick
syk
signal
essenti
event
effici
mhc
class
ii
epitop
peptid
load
case
crosspresent
mutat
fccr
disrupt
syk
associ
fail
deliv
intern
antigen
ic
lysosom
bonnerot
et
al
syk
defici
result
reduc
mhc
class
iidm
molecul
associ
intern
antigen
le
roux
et
al
evid
icfacilit
class
ii
antigen
present
viral
glycoprotein
rabi
g
free
antigen
enter
earli
endosom
kinet
similar
antibodi
bound
protein
thereaft
ic
becam
local
late
endolysosom
time
coloc
slow
recycl
endosom
rapid
recycl
endosom
marker
free
antigen
associ
vesicl
st
pierr
et
al
therefor
ic
may
facilit
antigen
deliveri
vesicl
late
endocyt
matur
step
mhc
class
ii
present
notion
inevit
disagre
shallow
target
report
crosspresent
discuss
previous
discrep
possibl
result
differ
antibodi
use
experi
could
prefer
fccr
subtyp
associ
lead
distinct
rout
traffick
howev
consid
ic
gener
enhanc
class
class
ii
antigen
present
one
postul
bind
antibodi
uncharacter
manner
intercept
robust
proteolyt
grind
endolysosom
system
save
antigen
multipl
stage
eventu
surfac
present
one
main
mechan
enhanc
antigen
present
ic
b
cell
longer
biolog
retent
evid
trap
ic
follicular
dendrit
cell
fdc
szakal
et
al
b
kosco
et
al
report
great
quantiti
ic
attach
long
membran
process
fdc
szakal
et
al
fdc
high
fccriib
express
protein
level
qin
et
al
report
suggest
ic
intern
fccriib
bergtold
et
al
consist
observ
fdc
b
cell
express
fc
receptor
ic
intern
fccriib
retain
cytoplasm
antigen
within
complex
kept
nativ
form
made
avail
b
cell
via
surfac
recycl
bergtold
et
al
exact
order
baton
exchang
report
ic
initi
trap
lymph
node
subcapsular
macrophag
b
cell
act
intermedi
fetch
send
complex
fdc
phan
et
al
fdc
receiv
complementco
ic
nonspecif
b
cell
follow
endocytosi
sort
complex
nondegrad
compart
extend
resurfac
heester
et
al
furthermor
fdcassoci
ic
play
role
bcr
hypermutagenesi
gener
highaffin
antibodi
wu
et
al
type
ii
fccr
also
implic
bcell
activ
igg
glycosyl
asparagin
biantennari
core
glycan
serv
base
addit
sugar
moieti
includ
fucos
galactos
bisect
nacetylglucosamin
sialic
acid
etc
complex
glycosyl
event
control
igg
conform
state
determin
preferenti
bind
either
type
type
ii
fccr
instanc
sialyl
reduc
bind
fc
type
increas
bind
type
ii
receptor
pincet
et
al
treatment
remov
moieti
suppress
ankl
swell
model
serum
transfer
arthriti
prolong
surviv
mous
strain
autoantibodyinduc
lupuslik
diseas
albert
et
al
target
ova
dc
via
without
concomit
activ
via
induc
antibodi
respons
suppress
dth
delay
type
hypersensit
respons
antiserum
mice
transfer
new
host
challeng
antigen
full
complement
extens
reduct
antigenspecif
detect
accompani
reduc
dth
respons
well
result
suggest
antibodi
produc
origin
host
without
dc
activ
signal
immunosuppress
inde
antibodi
produc
without
sialyl
rate
higher
treatment
due
higher
level
sialyltransferas
plasma
cell
oefner
et
al
reduct
antibodi
product
dth
respons
independ
fccriib
involv
type
ii
receptor
implic
oefner
et
al
type
ii
fccr
engag
import
consider
vaccin
trival
inactiv
influenza
vaccin
tiv
immun
individu
massspec
analysi
show
signific
glycosyl
pattern
chang
recipi
interestingli
subtl
differ
glycosyl
exist
antibodi
pool
found
predictor
respond
nonrespond
vaccin
wang
et
al
addit
recent
report
human
volunt
tiv
led
peak
product
haspecif
sialyl
igg
plasmablast
one
week
immun
follow
drop
abund
week
three
elev
result
glycosyltransferas
express
earli
respond
b
cell
importantli
sialyl
igg
via
trigger
fccriib
express
known
threshold
setter
bcr
signal
wang
et
al
result
alter
antibodybind
affin
pattern
fc
glycosyl
associ
protect
efficaci
given
antibodi
palivizumab
human
mab
respiratori
syncyti
viru
rsv
deriv
anim
cell
cultur
heterogen
glycosyl
pattern
antibodi
deriv
plant
cell
nicotiana
benthamiana
xylosyland
fucosyltransferas
activ
delet
produc
glycan
palivizumabn
form
glycosyl
show
enhanc
fccriii
bind
better
protect
rsv
challeng
hiatt
et
al
ic
directli
activ
apc
via
activ
fccr
upon
ic
bind
receptor
itamsyk
interact
primari
signal
axi
phagocyt
activ
lead
full
spectrum
signal
event
involv
plc
mapk
nfjb
mocsai
et
al
accordingli
ic
trigger
dc
express
unexpectedli
matsubara
et
al
perreau
et
al
boross
et
al
addit
ic
suffici
trigger
dc
aggreg
entranc
lymphat
vessel
migrat
ln
manner
clatworthi
et
al
gener
activ
apc
link
fccr
signal
recent
suggest
ic
insid
cell
cytosol
antibodi
receptor
bind
fc
portion
activ
ubiquitin
event
event
independ
activ
nfkb
irf
pathway
ad
anoth
level
complex
ic
signal
mcewan
et
al
immunesuppress
effect
ic
equal
note
small
immun
complex
form
ivig
inhibit
macrophag
respons
ifnc
effect
mainli
mediat
igg
fc
bind
fccriii
surprisingli
independ
fccriib
parkmin
et
al
complement
inflammatori
recruit
ic
suppress
neutrophil
macrophag
chemotaxi
inhibit
result
unexpect
collabor
itim
tyrosin
phosphoryl
fccriib
itam
phosphoryl
syk
downstream
karsten
et
al
contrast
convent
understand
ic
form
chronic
infect
caus
inflammatori
respons
fccr
crosslink
recent
found
mice
clone
lcmv
long
term
infect
presenc
ic
resist
tand
bcell
deplet
rituximab
antibodi
block
activ
dc
agonist
effect
explain
competit
inhibit
longterm
presenc
excess
ic
wieland
et
al
similar
report
issu
immun
confirm
find
demonstr
addit
defect
crosspresent
shown
latter
suppress
depend
tsupport
antibodi
product
yamada
et
al
conclus
somewhat
echo
observ
influenza
infect
peak
antibodi
product
form
ic
block
antibodydepend
phagocytosi
astri
jakab
point
ic
neg
impact
immun
activ
summar
discuss
immun
regulatori
function
ic
engag
fccr
fig
categor
hiv
infect
experiment
work
ic
start
use
antibodi
target
viral
epitop
approach
form
ic
vivo
ic
form
antibodi
recogn
hiv
bind
site
region
promis
elicit
strong
neutral
antibodi
viru
mice
visciano
et
al
hioe
et
al
one
regionspecif
antibodi
mab
show
high
affin
larg
variant
subtyp
bind
antibodi
significantli
increas
access
region
mab
suggest
attach
open
region
mask
structur
common
detectionavert
strategi
hiv
kwong
et
al
pan
et
al
ic
elicit
neutral
antibodi
balbc
mice
hioe
et
al
ic
form
mab
bind
outsid
bind
site
induc
neutral
antibodi
panel
hiv
strain
although
enhanc
alon
pronounc
presenc
cholera
toxin
lp
adjuv
breadth
result
antisera
neutral
divers
hiv
isol
widen
liao
et
al
recent
broadli
neutral
antibodi
bnab
seen
great
success
bnabproduc
b
cell
identifi
hiv
ic
preform
vaccin
prepar
consequ
antibodi
bind
endogen
antigen
signal
via
activ
receptor
induc
adcc
macrophag
nk
cell
lead
lysi
tumor
infect
cell
signal
via
fccr
dendrit
cell
result
enhanc
antigen
uptak
upregul
antigen
present
mhc
class
iirestrict
cell
cell
via
crosspresent
ic
retain
lymphoid
tissu
via
deposit
fccriibmedi
endocytosi
extend
antigen
avail
bcell
activ
result
increas
antibodi
respons
immun
memori
induct
differ
glycosyl
pattern
fc
regul
preferenti
bind
type
type
ii
fccr
control
state
inflamm
sialyl
fc
preferenti
bind
type
ii
fccr
particular
help
set
threshold
product
highaffin
antibodi
beyond
direct
erad
hiv
mous
model
approxim
human
mother
child
transmiss
frcase
virusinfect
neonat
mice
develop
erythroleukemia
reach
adulthood
neonat
deliveri
specif
mab
boost
antibodi
protect
tcell
respons
result
surviv
treat
mice
comparison
total
mortal
untreat
control
protect
mediat
adcc
format
virusantibodi
ic
michaud
et
al
viral
hepat
b
anoth
persist
infect
treat
ic
therapeut
vaccin
hbv
vaccin
model
duckl
infect
duck
hepat
b
viru
dhbv
treat
ic
dhbsag
complex
rabbit
antidhb
link
staphylococcu
aurea
bacteria
solid
matrix
complex
treat
duck
clear
viremia
antigenemia
three
inject
wen
et
al
efficaci
icbas
vaccin
hbv
infect
studi
mice
ic
form
nonspecif
igg
igm
antibodi
show
minim
enhanc
fab
fraction
specif
antibodi
hbsag
ic
stimul
cell
avid
turn
induc
antibodi
product
vivo
celi
et
al
icmedi
effect
follow
seroconvers
hbsab
posit
hbsagtransgen
mice
indic
selfantigen
toler
break
zheng
et
al
subsequ
dc
induc
chronic
hepat
b
patient
pbmc
stimul
either
hbsag
antibodi
ic
vitro
express
function
marker
includ
mhc
class
ii
found
increas
ic
stimul
furthermor
cell
patient
incub
stimul
dc
higher
level
ifnc
observ
icstimul
group
yao
et
al
use
lentiviru
vector
code
hbsag
either
alon
fuse
fc
domain
mous
fusion
version
induc
much
higher
tcell
activ
recipi
mice
well
elev
tcell
respons
antibodi
product
hong
et
al
simplifi
vaccin
protocol
meng
et
al
produc
hbsagfc
fusion
protein
use
immun
hbsagtransgen
mice
result
predomin
product
cytokin
reduc
serum
hbsag
level
meng
et
al
encourag
experiment
find
human
hbsag
ic
adsorb
alum
use
immun
hbv
chronic
hepat
b
patient
pilot
studi
recipi
show
substanti
reduct
serum
hbv
dna
hbeag
convert
neg
wen
et
al
phase
clinic
trial
healthi
subject
receiv
variou
amount
hbsag
ic
prepar
develop
antibodi
immunogen
simultan
increas
serum
ifnc
xu
et
al
outcom
one
dose
use
immun
chronic
hepat
b
patient
five
ten
patient
respond
show
log
decreas
serum
hbv
dna
loss
mark
reduct
hbeag
appear
antihbeag
two
patient
develop
antihbsag
antibodi
xu
et
al
phase
clinic
trial
hbeagposit
chronic
hepat
b
patient
immun
six
inject
ic
end
posttrial
followup
hbeag
seroconvers
rate
ic
placebo
group
respect
p
xu
et
al
addit
vaccin
trial
hiv
hbv
smaller
scale
effort
control
infect
report
ctl
respons
influenza
viru
infect
reduc
age
popul
young
balbc
mount
strong
cytolyt
respons
discern
differ
intens
flu
np
antigen
follow
inocul
live
kill
viru
prepar
viru
plu
npspecif
antibodi
ic
significantli
restor
respons
age
mice
enhanc
kill
associ
increas
ifnc
product
cell
due
rapid
spread
high
rate
mutagenesi
emphasi
influenza
infect
control
gener
bnab
conserv
region
hemagglutinin
ha
okuno
et
al
okuno
et
al
ekiert
et
al
one
version
antibodi
target
stem
region
type
type
ii
isol
block
membran
fusion
addit
bind
antibodi
induc
fccrdepend
adcc
suggest
involv
ic
wu
et
al
ebola
infect
sever
bcell
clone
highli
potent
gpspecif
neutral
antibodi
diseas
survivor
test
antibodi
also
mediat
adcc
via
fccr
mutant
fc
interf
receptor
bind
lost
cytotox
corti
et
al
francisella
tularensi
ft
caus
pathogen
tularemia
dc
coat
monoclon
antibodytr
ft
deliv
intranas
protect
host
subsequ
challeng
effect
affect
absenc
fccriib
suggest
preferenti
engag
activ
fccr
pham
et
al
malaria
infect
found
fccr
bind
critic
uptak
ic
mcclintock
et
al
one
studi
mortal
plasmodium
berghei
infect
often
lethal
prevent
antiserum
immun
mice
transfer
infect
mice
protect
elimin
absenc
fccr
cchain
pleass
addit
phoolcharoen
et
al
transient
express
ebola
viru
glycoprotein
fuse
antibodi
heavi
chain
human
antibodi
nicotiana
benthamiana
tobacco
plant
purifi
fusion
protein
induc
high
titer
ebolaspecif
igg
antibodi
similar
induc
viruslik
particl
suggest
scheme
vastli
increas
product
capac
ic
prepar
phoolcharoen
et
al
urgent
product
ic
protect
popul
threat
rapidli
emerg
viral
infect
middl
east
respiratori
syndrom
mer
also
test
although
ic
gener
consid
conduc
antivir
immun
note
case
presenc
virusspecif
antibodi
increas
infect
phenomenon
call
antibodydepend
enhanc
ade
viral
infect
tirado
yoon
step
trial
hiv
gag
pol
nef
gene
cassett
insert
adeno
vector
howev
individu
preexist
immun
viru
show
greater
risk
hiv
infect
follow
immun
buchbind
et
al
advers
effect
seen
addit
virus
dengu
goncalvez
et
al
measl
iankov
et
al
dozen
other
suhrbier
la
linn
fccrfacilit
viru
entri
skew
cytokin
profil
may
main
culprit
import
consider
assess
ic
immun
regulatori
function
cancer
immunotherapi
seen
tremend
stride
technolog
develop
immun
checkpoint
blockag
basic
concept
reduc
neg
regul
adapt
immun
mainli
target
anoth
modal
antibodybas
cancer
therapi
target
surfac
factor
critic
tumor
cell
growth
egfr
vegf
optim
fccr
ligat
import
consider
nimmerjahn
ravetch
concurr
progress
icbas
intervent
remain
altern
due
low
side
effect
antibodi
bind
tumor
surfac
antigen
trigger
adcc
fccr
engag
import
activ
signal
tumor
lysi
moalli
et
al
larg
number
experi
carri
use
variant
tumor
model
ic
shown
mediat
tumor
suppress
via
prophylact
therapeut
memoryinduc
effect
rafiq
et
al
mice
challeng
tumorexpress
ova
antigen
inject
dc
puls
ovacontain
ic
ova
antibodi
alon
inhibit
tumor
growth
furthermor
treatment
dc
load
ic
cure
mice
bear
establish
tumor
protect
mediat
dcic
immun
longstand
induc
memori
respons
recipi
vaccin
ova
rafiq
et
al
addit
specif
antibodi
target
antigen
express
wholecel
vaccin
shown
enhanc
antigenspecif
tcell
activ
memori
develop
protect
host
tumor
challeng
wolpo
et
al
kim
et
al
load
antibodi
myeloma
cell
surfac
heparan
sulfat
proteoglycan
express
cancer
cell
induc
hla
antigen
present
mhc
allelematch
donor
result
cytotox
tcell
activ
dhodapkar
et
al
antibodi
serv
facilit
overal
antigen
present
dc
ensu
cytotox
elicit
human
ctl
direct
toward
tumor
antigen
dhodapkar
et
al
fccr
play
import
role
icmedi
tumor
immun
experi
found
antibodi
coat
alter
level
uptak
tumor
cell
yet
block
fccr
significantli
reduc
antigenspecif
tcell
prolifer
dhodapkar
et
al
suggest
regulatori
role
fccr
mostli
step
beyond
opson
primarili
dc
matur
preferenti
induct
tumor
immun
achiev
finetun
signal
intens
ratio
activ
vs
inhibitori
fccr
concept
propos
ravetch
et
al
nimmerjahn
ravetch
instanc
tumorspecif
antibodi
found
fc
bind
activ
fccr
much
higher
intens
inhibitori
fccriib
preferenti
bind
particularli
fccriv
endow
strong
antitumor
effect
nimmerjahn
ravetch
signal
fccr
icmedi
immun
therapi
lead
vaccin
effect
especi
properli
select
fccr
engag
recent
paper
mice
challeng
tumor
surviv
presenc
antibodi
protect
lost
absenc
total
activ
fccr
expect
prime
mice
develop
immun
respons
reject
subsequ
challeng
neoantigen
tumor
dilillo
ravetch
lymphocyt
prime
mice
mice
dcspecif
delet
fccriv
transfer
new
host
former
transfus
show
better
tumor
resist
latter
mice
suggest
role
receptor
mediat
vaccin
effect
dilillo
ravetch
concept
test
human
mous
system
fc
region
mous
mab
replac
human
counterpart
total
replac
mfccr
hfccr
host
found
mutat
fc
allow
better
bind
hfccriiia
iia
compar
iiia
alon
protect
host
best
extent
dilillo
ravetch
overal
case
antipersist
viral
infect
select
pair
igg
fccr
subtyp
vivo
may
repres
promis
direct
icmedi
cancer
therapi
lastli
intracellular
tumor
antigen
often
shield
immun
recognit
becom
stimulatori
presenc
ic
tumor
antigen
consid
strictli
intracellular
howev
combin
like
stress
tumor
cell
ensu
releas
intracellular
content
inject
mab
result
signific
wolin
tumor
growth
inhibit
specif
combin
caus
antigen
epitop
spread
wherebi
intracellular
tumor
antigen
also
induc
tcell
activ
noguchi
et
al
demand
employ
ic
technolog
diseas
prevent
treatment
make
urgent
task
studi
effect
basic
clinic
set
tabl
one
oldest
technolog
immun
therapi
track
record
safeti
simplic
ic
valuabl
day
enorm
breakthrough
direct
downsid
icbas
intervent
also
clear
rel
low
clinic
efficaci
often
unpredict
clinic
experiment
result
howev
grow
understand
fccr
preferenti
bind
igg
subtyp
modern
biomed
engin
steer
desir
pair
futur
outcom
like
chang
hindsight
understand
built
vaccin
design
time
sever
largescal
clinic
trial
might
seen
differ
like
favor
effect
case
hiv
prophylaxi
ic
format
result
undesir
cytokin
profil
exist
antibodi
target
adeno
vector
two
factor
like
address
via
precis
target
activ
fccr
icbas
antihbv
vaccin
immun
therapi
firsthand
monitor
respond
cell
fccr
express
built
protocol
nextstag
clinic
trial
time
person
medicin
ic
prepar
tailor
individu
fccr
polymorph
could
within
reach
well
address
fccr
bind
mandatori
start
point
addit
effort
need
understand
precis
antigen
traffick
consequ
antibodi
bind
well
map
inflammatori
pathway
tissu
target
desir
immun
protect
vari
pathogen
pathogen
entri
portal
also
vastli
differ
specif
ic
prepar
made
induc
antibodi
respons
optim
protect
instanc
antitumor
antivir
immun
reli
cytolyt
tcell
activ
ic
vaccin
design
target
shallow
endocyt
compart
highli
ideal
admittedli
icmedi
immun
regul
intens
investig
class
immun
adjuv
howev
mechanist
research
crucial
futur
breakthrough
icbas
human
diseas
intervent
strongest
assur
maintain
continu
develop
old
biomed
technolog
